[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 42 of about 42
1. Moll A, Krenauer A, Bierbach U, Till H, Hirsch W, Leuschner I, Schmitz N, Wittekind C, Aigner T: Mixed hepatoblastoma and teratoma of the liver in a 3-year-old child: a unique combination and clinical challenge. Diagn Pathol; 2009;4:37

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed hepatoblastoma and teratoma of the liver in a 3-year-old child: a unique combination and clinical challenge.
  • Primary liver tumors in children are rare with malignant hepatoblastoma being the most common neoplasm.
  • In this report, we describe the diagnosis and clinical management of a large liver tumor in a 3-year-old child that displayed the features of both, conventional hepatoblastoma and malignant teratoma.
  • Histological and immunohistological examination of the resected tumor specimen additionally showed tumor areas of very different differentiation pattern intermixed with each other, namely areas of hepatoblastoma-typical and neuroblastoma-like morphology as well as areas of rhadomyosarcomatous differentiation.After chemotherapy the tumor size increased and an extended right hemihepatectomy was performed.
  • Post-operatively, the general condition of the child improved and adjuvant chemotherapy was started two weeks later.
  • 36 months after initial diagnosis the patient is healthy, in good general condition, and without any sign of residual tumor disease.Overall, we describe the diagnosis and clinical management of a large liver tumor in a 3-year-old child that displayed the features of both, conventional hepatoblastoma and malignant teratoma and was designated as mixed hepatoblastoma and teratoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Oncol. 2007 Nov;16(3):195-203 [17714939.001]
  • [Cites] Diagn Pathol. 2009;4:17 [19523243.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):832-9 [10673525.001]
  • [Cites] Histopathology. 2003 Sep;43(3):306-8 [12940789.001]
  • [Cites] Indian J Pathol Microbiol. 2003 Oct;46(4):658-9 [15025371.001]
  • [Cites] Pediatr Radiol. 2006 Mar;36(3):183-6 [16404556.001]
  • [Cites] J Clin Oncol. 1991 Dec;9(12):2167-76 [1720452.001]
  • [Cites] Cancer. 1993 Nov 15;72(10):2910-3 [8221556.001]
  • [Cites] J Clin Gastroenterol. 1993 Dec;17(4):308-10 [8308217.001]
  • [Cites] Eur J Surg Oncol. 2005 Dec;31(10):1160-5 [16157464.001]
  • [Cites] Cancer. 1986 Jun 1;57(11):2168-74 [2421866.001]
  • (PMID = 19909520.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2784753
  •  go-up   go-down


2. Eghtesad B, Marsh WJ, Cacciarelli T, Geller D, Reyes J, Jain A, Fontes P, Devera M, Fung J: Liver transplantation for growing teratoma syndrome: report of a case. Liver Transpl; 2003 Nov;9(11):1222-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation for growing teratoma syndrome: report of a case.
  • Liver transplantation is a well-established treatment for liver failure and for a selected group of patients with hepatic tumors.
  • The growing teratoma syndrome refers to the phenomenon whereby germ cell tumors enlarge after chemotherapy despite complete eradication of malignant cells and normalization of serum tumor markers.
  • We present the case of a young patient with rapidly growing teratomatous masses in his liver who was treated with liver transplantation from a live donor.
  • [MeSH-major] Liver Neoplasms / secondary. Liver Neoplasms / surgery. Liver Transplantation. Teratoma / pathology. Teratoma / surgery. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Humans. Male. Neoplasm Invasiveness. Orchiectomy. Syndrome. Tomography, X-Ray Computed


3. Lee HL, Liu YY, Yeh CN, Chiang KC, Chen TC, Jan YY: Primary squamous cell carcinoma of the liver: a successful surgically treated case. World J Gastroenterol; 2006 Sep 7;12(33):5419-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary squamous cell carcinoma of the liver: a successful surgically treated case.
  • Primary squamous cell carcinoma (SCC) of the liver is rare.
  • Primary SCC of the liver has been reported to be associated with hepatic teratoma, hepatic cyst, or hepatolithiasis.
  • Complete remission of poorly differentiated SCC of the liver could be achieved by systemic chemotherapy followed by surgery or remarkably respond to hepatic arterial injection of low dose chemotherapeutic drugs.
  • Here we report the first case of primary SCC of the liver presenting as a solid tumor and receiving successful hepatic resection with 9-mo disease free survival.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / surgery. Liver Neoplasms / diagnosis. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Disease-Free Survival. Humans. Liver / pathology. Liver / ultrasonography. Male. Remission Induction. Treatment Outcome. Ultrasonography

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Int. 2003 Feb;53(2):90-7 [12588436.001]
  • [Cites] Kurume Med J. 2003;50(1-2):71-5 [12971268.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2004 Oct;16(10):1051-6 [15371931.001]
  • [Cites] Cancer. 1976 Nov;38(5):2002-5 [991114.001]
  • [Cites] Gut. 1990 Nov;31(11):1333-4 [2253922.001]
  • [Cites] Cell Prolif. 2005 Dec;38(6):407-21 [16300653.001]
  • [Cites] HPB Surg. 1992 Apr;5(3):203-8 [1510892.001]
  • [Cites] J Surg Oncol. 1994 Nov;57(3):210-2 [7967614.001]
  • [Cites] Acta Cytol. 1996 Mar-Apr;40(2):339-45 [8629424.001]
  • [Cites] Tumori. 2005 Jan-Feb;91(1):71-2 [15850008.001]
  • [Cites] Aust N Z J Surg. 1991 Sep;61(9):720-2 [1877947.001]
  • (PMID = 16981283.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4088220
  •  go-up   go-down


Advertisement
4. Chan KL, Tang MH, Tse HY, Tang RY, Lam HS, Lee CP, Tam PK: Factors affecting outcomes of prenatally-diagnosed tumours. Prenat Diagn; 2002 May;22(5):437-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Medical records of all fetuses referred to our institutions with antenatally-diagnosed tumours were reviewed for the type and location of the tumours, results of treatment and/or causes of death.
  • RESULTS: From January 1994 to May 2001, there were 15 fetuses with antenatally- diagnosed tumours: mesoblastic nephroma (MN) (n=2); neuroblastoma (NB) (n=2); cystic hygroma (CH) (n=3); intracranial germ cell tumour (IGCT) (n=2); sacrococcygeal teratoma (SCT) (n=3) and haemangioma (liver, n=2; limb, n=1).
  • One baby had cardiac failure resulting from a lower limb haemangioma and needed drug therapy.
  • All solid tumours (MN, NB, SCT) of the live births had no recurrence after surgery with or without adjuvant chemotherapy.
  • [MeSH-minor] Adult. Female. Gestational Age. Humans. Pregnancy. Retrospective Studies. Survival Analysis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Fetal Health and Development.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 John Wiley & Sons, Ltd.
  • (PMID = 12001204.001).
  • [ISSN] 0197-3851
  • [Journal-full-title] Prenatal diagnosis
  • [ISO-abbreviation] Prenat. Diagn.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


5. Ponce de León Roca J, Villavicencio Mavrich H: [Growing teratoma syndrome]. Arch Esp Urol; 2000 Jul-Aug;53(6):547-52
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Growing teratoma syndrome].
  • [Transliterated title] Síndrome del "Growing teratoma".
  • OBJECTIVE: To review our series of patients with the growing teratoma syndrome (GTS) and to compare our results with those reported in the literature.
  • METHODS: We reviewed the clinical records of our series of patients with GTS for age, location of the tumor mass before and after chemotherapy, clinical stage according to the Royal Marsden Hospital Classification, histological pattern of the primary tumor, number and type of surgical procedures performed and clinical course.
  • The mean age at the time of diagnosis was 23 years.
  • Histological analysis of the primary tumor showed mature teratoma in 11, ectodermal sinus tumor in 8, and both histological types in 4.
  • A total of 33 surgical procedures were performed: 25 retroperitoneal lymphadenectomy (7 with retrocrural involvement), 4 thoracotomy with segmental lung resection, 2 resection of supraclavicular adenopathy, 1 resection of liver metastasis, and 1 resection of inguinal adenopathy.
  • The 25 retroperitoneal lymphadenectomy performed due to GTS account for 16.2% of the 154 retroperitoneal lymphadenectomies that were performed during the same time period.
  • Follow-up showed recurrence in 10 patients (58.8%); 7 had mature teratoma and 3 had malignant tumor.
  • CONCLUSIONS: Mature teratoma lesions can appear in different sites, the most frequent being the retroperitoneum and lung.
  • These lesions can appear before or during chemotherapy or after a disease-free interval.
  • The treatment of choice is resection of the mass, if possible in a single session to prevent malignant degeneration or compression of the adjacent structures.
  • We institute treatment early since an increase in size will make surgical treatment difficult, compromise organs and favor recurrence.
  • [MeSH-major] Teratoma. Testicular Neoplasms

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11002523.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] SPAIN
  • [Number-of-references] 25
  •  go-up   go-down


6. Korfel A, Fischer L, Foss HD, Koch HC, Thiel E: Testicular germ cell tumor with rhabdomyosarcoma successfully treated by disease-adapted chemotherapy including high-dose chemotherapy: case report and review of the literature. Bone Marrow Transplant; 2001 Oct;28(8):787-9
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular germ cell tumor with rhabdomyosarcoma successfully treated by disease-adapted chemotherapy including high-dose chemotherapy: case report and review of the literature.
  • Treatment and prognosis have not been well characterized in germ cell tumors (GCT) with a malignant nongerm cell component.
  • We report a rare case of mixed GCT composed of seminoma, teratoma and rhabdomyosarcoma with the rhabdomyosarcomatous component metastasized into the liver and bone marrow (BM) causing hypercalcemia.
  • The patient was treated with differentiation-tailored chemotherapy (CHT) including a disease-adapted high-dose (HD) CHT regimen with purified autologous PBSCT (APBSCT) and pamidronate.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Neoplasms, Multiple Primary / drug therapy. Rhabdomyosarcoma / drug therapy. Seminoma / drug therapy. Teratoma / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Bone Marrow / pathology. Carboplatin / administration & dosage. Cell Differentiation. Cisplatin / administration & dosage. Combined Modality Therapy. Diphosphonates / therapeutic use. Epirubicin / administration & dosage. Etoposide / administration & dosage. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Lumbar Vertebrae. Male. Middle Aged. Neoplasm Metastasis. Orchiectomy. Remission Induction. Seizures / etiology. Spinal Neoplasms / drug therapy. Spinal Neoplasms / secondary. Spinal Neoplasms / therapy. Transplantation, Autologous

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11781632.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Diphosphonates; 3Z8479ZZ5X / Epirubicin; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; OYY3447OMC / pamidronate; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


7. Hartmann JT, Rick O, Oechsle K, Kuczyk M, Gauler T, Schöffski P, Schleicher J, Mayer F, Teichmann R, Kanz L, Bokemeyer C: Role of postchemotherapy surgery in the management of patients with liver metastases from germ cell tumors. Ann Surg; 2005 Aug;242(2):260-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of postchemotherapy surgery in the management of patients with liver metastases from germ cell tumors.
  • OBJECTIVE: To evaluate the role of postchemotherapy adjunctive surgery in patients with liver metastases from germ cell cancer (GCT).
  • PATIENTS AND METHODS: Forty-three male patients with nonseminoma were treated in different multicenter treatment protocols between 1990 and 1999, and they underwent hepatic surgery.
  • RESULTS: Thirty-five of 43 patients (81%) were initially diagnosed with liver metastases and advanced GCT, and 8 patients (19%) presented with metachronous liver metastases after a median interval of 16 months (range, 6-103 months).
  • Twelve patients (28%) had isolated liver metastases after completion of chemotherapy, while 31 patients (72%) had additional residual extrahepatic tumor masses.
  • Liver surgery included tumor excision or segmentectomy in 32 patients (74%) and hepatectomy (right/left) or resection of multiple segments in 11 patients (26%).
  • Histologic analysis of postchemotherapy resected residua yielded necrosis in 67%, teratoma in 12%, and viable cancer in 21%.
  • Additional resections at other sites have been performed in 31 patients revealing necrosis in 61% (n = 19), teratoma in 29% (n = 9), and vital carcinoma in 10% (n = 3).
  • In 39% of patients, histologic findings differed among liver and other resection sites.
  • Refractoriness to chemotherapy was associated with a shorter survival after surgery, and a trend was seen in patients with elevation of AFP.
  • CONCLUSION: The high rate of viable cancer and teratoma found in liver specimens, differing histologic results at residual tumor locations, and the high survival rate achieved support a multidisciplinary approach including resection of liver masses since no accurate selection of patients can narrow the use of surgery.
  • [MeSH-major] Germinoma / secondary. Germinoma / surgery. Liver Neoplasms / secondary. Liver Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy. Hepatectomy. Humans. Male. Middle Aged. Neoplasm, Residual / pathology. Teratoma / drug therapy. Teratoma / mortality. Teratoma / secondary. Teratoma / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 1999 Oct-Nov;6(7):640-4 [10560848.001]
  • [Cites] N Engl J Med. 1997 Jul 24;337(4):242-53 [9227931.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):578-87 [11505402.001]
  • [Cites] Ann Oncol. 2002 Jul;13(7):1017-28 [12176779.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3310-7 [12947067.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4083-91 [14568987.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1377-99 [15319245.001]
  • [Cites] Ann Thorac Surg. 1983 Nov;36(5):524-8 [6195980.001]
  • [Cites] Br J Cancer. 1984 Nov;50(5):601-9 [6093838.001]
  • [Cites] Cancer. 1986 Mar 1;57(5):978-83 [3002596.001]
  • [Cites] Cancer. 1989 Feb 1;63(3):440-5 [2912523.001]
  • [Cites] J Clin Oncol. 1990 Oct;8(10):1683-94 [2170590.001]
  • [Cites] J Urol. 1991 Feb;145(2):300-2; discussion 302-3 [1988722.001]
  • [Cites] Cancer. 1994 Aug 15;74(4):1329-34 [8055456.001]
  • [Cites] Br J Cancer. 1994 Nov;70(5):960-5 [7524606.001]
  • [Cites] J Clin Oncol. 1995 May;13(5):1177-87 [7537801.001]
  • [Cites] J Clin Oncol. 1996 Jun;14(6):1765-9 [8656244.001]
  • [Cites] Ann Oncol. 1997 Jun;8(6):531-8 [9261521.001]
  • [Cites] Eur J Cancer. 1997 May;33(6):843-7 [9291803.001]
  • [Cites] Br J Urol. 1997 Oct;80(4):653-7 [9352708.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):594-603 [9053482.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):81-8 [11134198.001]
  • (PMID = 16041217.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1357732
  •  go-up   go-down


8. Bilici A, Ustaalioglu BB, Seker M, Kayahan S: Case report: soft tissue metastasis from immature teratoma of the testis: second case report and review of the literature. Clin Orthop Relat Res; 2010 Sep;468(9):2541-4
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: soft tissue metastasis from immature teratoma of the testis: second case report and review of the literature.
  • BACKGROUND: Testicular cancer, like other histopathologic types, commonly metastasizes to the lungs, liver, and brain.
  • Spread to soft tissue, however, is rare with only four cases with seminoma reported.
  • However, one case with metastasis of testicular immature teratoma to soft tissue was documented previously.
  • CASE DESCRIPTION: We report the case of a 38-year-old man with recurrent immature teratoma of the testis who presented with a painless soft tissue mass in the left thigh previously treated with standard chemotherapy.
  • After removal of the soft tissue mass, his serum alpha-fetoprotein level had returned to the normal range.
  • LITERATURE REVIEW: To our knowledge, this is the second case of immature teratoma of the testis metastasized to soft tissue.
  • PURPOSES AND CLINICAL RELEVANCE: We suggest that for a man with testicular cancer who has a soft tissue mass, metastasis of soft tissue from testicular cancer and other solid malignancies should be considered in the differential diagnosis of a soft tissue mass together with primary soft tissue sarcoma.
  • [MeSH-major] Soft Tissue Neoplasms / secondary. Teratoma / secondary. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Brain Neoplasms / therapy. Chorionic Gonadotropin, beta Subunit, Human / blood. Cranial Irradiation. Humans. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Magnetic Resonance Imaging. Male. Orchiectomy. Thigh. Treatment Outcome. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Skeletal Radiol. 2000 May;29(5):270-4 [10883446.001]
  • [Cites] Br J Radiol. 2008 Jul;81(967):e188-90 [18559897.001]
  • [Cites] AJR Am J Roentgenol. 2002 Dec;179(6):1644; author reply 1644 [12438072.001]
  • [Cites] Jpn J Clin Oncol. 2004 Apr;34(4):210-4 [15121758.001]
  • [Cites] Br J Surg. 1970 Jul;57(7):529-30 [5427475.001]
  • [Cites] Urology. 1985 Apr;25(4):398-400 [2984822.001]
  • [Cites] AJR Am J Roentgenol. 1985 Dec;145(6):1165-71 [2998169.001]
  • [Cites] Dis Colon Rectum. 1987 Oct;30(10):805-8 [2820673.001]
  • [Cites] Ann Plast Surg. 1993 Oct;31(4):377-8 [8239441.001]
  • [Cites] Clin Orthop Relat Res. 1998 Oct;(355):272-81 [9917613.001]
  • [Cites] Acta Neurol Belg. 2005 Sep;105(3):178-9 [16255156.001]
  • [Cites] Eur Urol. 2005 Dec;48(6):885-94 [16126333.001]
  • [Cites] Singapore Med J. 2007 Mar;48(3):e77-80 [17342276.001]
  • [Cites] Eur J Surg Oncol. 2007 May;33(4):508-11 [17081724.001]
  • [Cites] Cancer. 2008 Jan 1;112(1):193-203 [18040999.001]
  • [Cites] JAMA. 2008 Feb 13;299(6):672-84 [18270356.001]
  • [Cites] Ann Surg Oncol. 2000 Aug;7(7):526-34 [10947022.001]
  • (PMID = 19937408.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AFP protein, human; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins
  • [Number-of-references] 17
  • [Other-IDs] NLM/ PMC2919860
  •  go-up   go-down


9. Cöl C: Immature teratoma in both mediastinum and liver of a 21-Year-old female patient. Acta Med Austriaca; 2003;30(1):26-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immature teratoma in both mediastinum and liver of a 21-Year-old female patient.
  • We present a case of an immature teratoma of the liver and the mediastinum.
  • Abdominal ultrasonography showed a liver tumor which is located in the right lobe and composed of cystic and solid elements.
  • Computed tomography (CT) also showed a big mass which contained multiple high density, nodular, semi-solid, heterogenic structures in the liver and another mass which contained multiple low density cystic lesions in the anterior mediastinum.
  • Right hepatic lobectomy was performed for liver tumour.
  • Intraoperative frozen sections of the liver tumor revealed teratoma.
  • But the final pathological diagnosis was immature teratoma.
  • Chemotherapy was given after surgery.
  • The patient tolerated the procedure well and her postoperative course was unremarkable.
  • At the first follow up 4 months after surgery she was alive and well and there was no evidence of recurrence, but the patient died within seven months with hepatic recurrence and spreading metastasis.
  • [MeSH-major] Liver Neoplasms / pathology. Liver Neoplasms / surgery. Teratoma / pathology. Teratoma / surgery
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Biopsy, Needle. Combined Modality Therapy. Female. Humans. Tomography, X-Ray Computed. Ultrasonography

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12558563.001).
  • [ISSN] 0303-8173
  • [Journal-full-title] Acta medica Austriaca
  • [ISO-abbreviation] Acta Med. Austriaca
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


10. Kurata A, Hirano K, Nagane M, Fujioka Y: Immature teratoma of the ovary with distant metastases: favorable prognosis and insights into chemotherapeutic retroconversion. Int J Gynecol Pathol; 2010 Sep;29(5):438-44
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immature teratoma of the ovary with distant metastases: favorable prognosis and insights into chemotherapeutic retroconversion.
  • We present a case of a young woman with an immature teratoma of the right ovary that showed systemic metastases.
  • Pathologic diagnosis was an immature teratoma, grade 2.
  • As brain, lung, and liver metastases were discovered within 2 years after the operation, sequential resections of the metastatic foci were performed before chemotherapy as well as during the early and late stages of chemotherapy.
  • The resected specimens of each metastatic focus contained histologically more mature elements of the primary immature teratoma and exhibited a decrease in the Ki-67 labeling index, the later the resection was performed.
  • As far as we know, this is the first case of brain metastasis stemming from an immature teratoma of the ovary.
  • In addition, it was highly suggestive that chemotherapy itself was the main etiological factor for the promotion of maturation.
  • [MeSH-major] Ovarian Neoplasms / pathology. Teratoma / secondary
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Brain Neoplasms / surgery. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20736769.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


11. Li Y, Jiang Y, Song S: [Diagnosis and treatment of primary retroperitoneal teratoma]. Zhonghua Wai Ke Za Zhi; 2000 Dec;38(12):892-4
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of primary retroperitoneal teratoma].
  • OBJECTIVE: To study the diagnosis and treatment of primary retroperitoneal teratoma in adults.
  • METHODS: The clinical data of 36 adult patients with primary retroperitoneal teratoma were reviewed.
  • All patients, except one with liver metastasis, underwent radical resection.
  • CONCLUSIONS: Malignant metastasis of retroperitoneal teratoma is closely related to the age of adults.
  • Early radical resection is the optimal treatment.
  • Adjuvant chemotherapy can induce a short-time remission in those with germ cell elements.

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11832188.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


12. Djordjevic B, Euscher ED, Malpica A: Growing teratoma syndrome of the ovary: review of literature and first report of a carcinoid tumor arising in a growing teratoma of the ovary. Am J Surg Pathol; 2007 Dec;31(12):1913-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growing teratoma syndrome of the ovary: review of literature and first report of a carcinoid tumor arising in a growing teratoma of the ovary.
  • We report the first case of a secondary tumor arising from a peritoneal nodule of mature teratoma in a patient with growing teratoma syndrome (GTS) of the ovary.
  • The patient originally presented 19 years ago with an immature teratoma of the ovary and positive retroperitoneal lymph nodes.
  • After surgery and chemotherapy, mature teratomas recurred as abdominal and pelvic masses after 1, 6, and 19 years.
  • Upon the last recurrence, a trabecular carcinoid tumor developed in a mature teratoma associated with the liver.
  • On the basis of our review of ovarian GTS cases in the literature, we have found that ovarian GTS nodules tend to appear for the first time within 2 years of the initial primary.
  • [MeSH-major] Carcinoid Tumor / pathology. Liver Neoplasms / secondary. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Teratoma / secondary


13. Fan Q, Huang H, Lian L, Lang J: Characteristics, diagnosis and treatment of hepatic metastasis of pure immature ovarian teratoma. Chin Med J (Engl); 2001 May;114(5):506-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics, diagnosis and treatment of hepatic metastasis of pure immature ovarian teratoma.
  • OBJECTIVE: To analyze the characteristics of hepatic metastasis of pure immature ovarian teratoma and explore its proper diagnosis and treatment.
  • METHODS: Eighteen cases of hepatic metastasis of pure immature ovarian teratoma were included in this study.
  • The clinical stage, operation, chemotherapy and histopathology of primary and secondary tumors as well as the data from long term follow-ups were analyzed retrospectively.
  • RESULTS: All of the hepatic metastatic tumors were located on the surface of the liver.
  • The hepatic metastatic rate was 16.7% (3/18) in the standard adjuvant chemotherapy group but increased markedly to 31.2% (15/48) in the irregular chemotherapy group.
  • The surgical resection rate of hepatic metastasis of pure immature ovarian teratoma was 94.4% (17/18).
  • The follow-up time ranged from 3 to 205 months with a mean of 20.9 months.
  • CONCLUSIONS: The hepatic metastatic rate of pure immature ovarian teratoma could be decreased using standard adjuvant chemotherapy.
  • Suitable surgical treatment could reduce complications and improve the prognosis for patients.
  • [MeSH-major] Liver Neoplasms / secondary. Ovarian Neoplasms / pathology. Teratoma / pathology

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11780414.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


14. Gerl A, Hentrich M, Weber N, Schlemmer M, Hartenstein R, Hiddemann W: Clinical characteristics and outcome of late relapse after cisplatin-based chemotherapy of germ cell tumor. An update. J Clin Oncol; 2004 Jul 15;22(14_suppl):4529

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and outcome of late relapse after cisplatin-based chemotherapy of germ cell tumor. An update.
  • : 4529 Background: Late relapse of germ cell tumor (GCT) is defined as recurrence after an interval of more than 2 years from initial therapy.
  • METHODS: The charts of 37 patients treated for late relapse after cisplatin-based chemotherapy for GCT from 1983 through 2002 were reviewed (non-seminoma n=36, pure seminoma n=1).
  • RESULTS: Time to late relapse ranged from 25 to 191 months (median 66 months; > 5 years n=21 [57%], > 10 years n=5 [14%]).
  • The most frequently involved site was the retroperitoneum n=17 (46%) followed by mediastinum n=9 (24%), pelvis, retrocrural space, neck, lung and liver (each site n=4 [11%]).
  • 5 patients (14%) had a late relapse with pure teratoma.
  • 2 patients refused any treatment, 24 patients (65%) underwent chemotherapy as initial treatment for late relapse, 11 patients (30%) surgery.
  • After initial therapy for late relapse 19 patients (51%) achieved no evidence of diesase (NED) status, 9 of whom relapsed again (5 with a second late relapse).
  • After a median follow-up of 52 months (range, 9-168 months) 17 patients (46%) are alive with NED (15 of 27 patients [56%] with disease at one antomic site only), 10 patients (27%) continuously and 7 (19%) after further treatment.
  • 30 patients underwent chemotherapy for management of late relapse or subsequent recurrence, 3 (10%) of whom achieved a durable NED status to chemotherapy alone (1 patient to oral etoposide after failure of high-dose chemotherapy).
  • CONCLUSIONS: Resectable disease at one anatomic site is a predictor for favorable outcome of treatment for late relapse.
  • Durable response to chemotherapy alone is rare but occurs even in heavily pretreated patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016024.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Fan Q, Huang H, Lian L: [The characteristics diagnosis and treatment of hepatic metastasis of simple immature ovarian teratoma]. Zhonghua Fu Chan Ke Za Zhi; 2000 Oct;35(10):613-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The characteristics diagnosis and treatment of hepatic metastasis of simple immature ovarian teratoma].
  • OBJECTIVE: To analyze the characteristics of hepatic metastasis of pure immature ovarian teratoma and explore proper diagnosis and treatment.
  • METHODS: A total of 18 cases with hepatic metastasis of pure immature ovarian teratoma were involved in this study.
  • The clinical stage, operation, chemotherapy and histopathology of primary and secondary tumor as well as the data of long term follow-up were analyzed retrospectively.
  • RESULTS: All of the hepatic metastatic tumor located on the surface of liver, 66.1% (11/18) of them was clinically stage 3 and 44.4% (8/18) was grade 1 at first operation.
  • The hepatic metastatic rate was 16.7% (3/18) in standard adjuvant chemotherapy group but increased obviously to 31.2% (15/48) in irregular chemotherapy group.
  • The surgical resection rate of hepatic metastasis of pure immature ovarian teratoma was 94.4% (17/18).
  • The follow-up time ranged from 3-205 months with the mean of 20.9 months.
  • CONCLUSIONS: The hepatic metastatic rate of pure immature ovarian teratoma could be decreased by using standard adjuvant chemotherapy.
  • Suitable surgical treatment could reduce complication and improve the prognosis of this kind of patients.
  • [MeSH-major] Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Neoplasm Recurrence, Local / diagnosis. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / pathology. Teratoma / diagnosis

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11372414.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


16. Gordon MS, Battiato LA, Finch D, Goulet R Jr, Einhorn LH: Dramatic response of teratoma-associated non--germ-cell cancer with all-trans retinoic acid in a patient with nonseminomatous germ cell tumor. Am J Clin Oncol; 2001 Jun;24(3):269-71
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dramatic response of teratoma-associated non--germ-cell cancer with all-trans retinoic acid in a patient with nonseminomatous germ cell tumor.
  • A patient with nonseminomatous germ cell cancer, treated with standard chemotherapy, subsequently developed a pathologically confirmed metastatic undifferentiated adenocarcinoma (non-germ-cell elements) arising from residual teratoma.
  • Disease was present in both lobes of the liver and was deemed unresectable at the time of presentation.
  • After 60 days of oral therapy at a dose of 150 mg/m2/d (50 mg/m2 three times daily), the patient was found to have complete radiologic resolution of his hepatic metastases.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Germinoma / drug therapy. Neoplasms, Second Primary / drug therapy. Teratoma / drug therapy. Testicular Neoplasms / drug therapy. Tretinoin / therapeutic use


17. Fléchon A, Rivoire M, Berger N: [Surgery of residual masses after chemotherapy in patients with testicular cancer]. Rev Prat; 2007 Feb 28;57(4):389-98
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgery of residual masses after chemotherapy in patients with testicular cancer].
  • [Transliterated title] Chirurgie des masses résiduelles après chimiothérapie du cancer du testicule.
  • Cisplatin-based chemotherapy has dramatically improved the prognosis of germ cell tumours, but surgery, when applicable, remains a central part of treatment.
  • Forty five per cent and 10% of residual masses contain teratoma or active disease respectively.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Neoplasm, Residual / surgery. Neoplasms, Germ Cell and Embryonal / drug therapy. Neoplasms, Germ Cell and Embryonal / secondary. Neoplasms, Germ Cell and Embryonal / surgery. Testicular Neoplasms / drug therapy. Testicular Neoplasms / surgery
  • [MeSH-minor] Adult. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Brain Neoplasms / secondary. Brain Neoplasms / surgery. Combined Modality Therapy. Controlled Clinical Trials as Topic. Follow-Up Studies. Humans. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Lymphatic Metastasis. Male. Positron-Emission Tomography. Postoperative Complications. Prognosis. Prospective Studies. Radiotherapy Dosage. Retroperitoneal Space. Seminoma / drug therapy. Seminoma / radionuclide imaging. Seminoma / surgery. Teratoma / surgery. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17455741.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 52
  •  go-up   go-down


18. Collen J, Carmichael M, Wroblewski T: Metastatic malignant teratoma arising from mediastinal nonseminomatous germ cell tumor: a case report. Mil Med; 2008 Apr;173(4):406-9
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic malignant teratoma arising from mediastinal nonseminomatous germ cell tumor: a case report.
  • We present a case of primary mediastinal NSGCT with malignant transformation of a teratoma in an active duty airman who presented with a 12-cm anterior mediastinal mass and vertebral body lesion.
  • Chemotherapy for GCT normalized serum tumor markers with little effect on the mediastinal mass.
  • Serum tumor markers rose 3 months following resection with metastatic disease to bone and liver.
  • Chemotherapy targeting sarcoma induced a partial response, but the patient developed acute myeloid leukemia refractory to chemotherapy.
  • [MeSH-major] Leukemia, Myeloid, Acute. Mediastinal Neoplasms / pathology. Teratoma / secondary
  • [MeSH-minor] Adult. Dacarbazine / therapeutic use. Doxorubicin / therapeutic use. Fatal Outcome. Humans. Ifosfamide / therapeutic use. Male. Mesna / therapeutic use. Neoplasms, Germ Cell and Embryonal / pathology


19. Ozen H, Ekici S, Sozen S, Ergen A, Tekgül S, Kendi S: Resection of residual masses alone: an alternative in surgical therapy of metastatic testicular germ cell tumors after chemotherapy. Urology; 2001 Feb;57(2):323-7
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resection of residual masses alone: an alternative in surgical therapy of metastatic testicular germ cell tumors after chemotherapy.
  • METHODS: Seventy-five patients underwent resection of residual masses after chemotherapy.
  • RESULTS: The histologic features of the resected specimens were necrosis/fibrosis, teratoma, and viable cancer in 33.3%, 45.3%, and 21.3%, respectively.
  • Two patients had a relapse in the retroperitoneum, two in the thorax, and one in the liver.
  • [MeSH-major] Germinoma / drug therapy. Germinoma / surgery. Testicular Neoplasms / drug therapy. Testicular Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Ejaculation. Fibrosis. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Necrosis. Postoperative Complications. Retroperitoneal Neoplasms / secondary. Retrospective Studies. Survival Rate. Thoracic Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11182346.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Bokemeyer C, Schleucher N, Metzner B, Thomas M, Rick O, Schmoll HJ, Kollmannsberger C, Boehlke I, Kanz L, Hartmann JT: First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial. Br J Cancer; 2003 Jul 7;89(1):29-35
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial.
  • To determine the efficacy of first-line sequential high-dose VIP chemotherapy (HD-VIP) in patients with primary mediastinal nonseminomatous germ cell tumours (GCT), 28 patients were enrolled on a German multicentre trial.
  • High-Dose VIP chemotherapy consisted of 3-4 cycles of dose-intensive etoposide and ifosfamide plus cisplatin, q22days, each cycle followed by autologous peripheral blood stem cell transplantation plus granulocyte-colony stimulating factor (G-CSF) support.
  • Ten patients had mediastinal involvement as the only manifestation (36 %), 18 of 28 patients had additional metastatic sites, such as lung (n=17; 61%), liver (n=7; 25%), bone (n=5; 18%), lymph nodes (n=3; 11%) and CNS (n=3; 11%).
  • Two patients developed recurrence of GCT or teratoma.
  • Compared to data of an international database analysis including 253 patients with mediastinal nonseminoma treated with conventional chemotherapy, the results may indicate that HD-VIP results in an approximately 15% survival improvement.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Germinoma / drug therapy. Mediastinal Neoplasms / drug therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Etoposide / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Ifosfamide / administration & dosage. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Prospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1864-73 [11919246.001]
  • [Cites] Br J Urol. 1964 Jun;36:SUPPL:1-11 [14184707.001]
  • [Cites] JAMA. 1983 Oct 7;250(13):1733-41 [6684188.001]
  • [Cites] Cancer. 1984 Nov 1;54(9):1824-33 [6090001.001]
  • [Cites] J Clin Oncol. 1985 Mar;3(3):316-25 [2579212.001]
  • [Cites] Ann Intern Med. 1985 May;102(5):603-9 [2984971.001]
  • [Cites] J Clin Oncol. 1986 Mar;4(3):400-7 [2419524.001]
  • [Cites] J Clin Oncol. 1987 Aug;5(8):1290-4 [3040921.001]
  • [Cites] Ann Thorac Surg. 1987 Dec;44(6):578-82 [2446572.001]
  • [Cites] J Thorac Cardiovasc Surg. 1990 Feb;99(2):210-7 [2153877.001]
  • [Cites] Cancer. 1990 Apr 1;65(7):1641-6 [1690077.001]
  • [Cites] N Engl J Med. 1990 May 17;322(20):1425-9 [2158625.001]
  • [Cites] Cancer. 1991 Apr 15;67(8):2049-57 [1848473.001]
  • [Cites] J Clin Oncol. 1991 Jul;9(7):1163-72 [1710655.001]
  • [Cites] Br J Cancer. 1993 Mar;67(3):568-72 [8382512.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3450-6 [10550141.001]
  • [Cites] J Natl Cancer Inst. 2000 Jan 5;92(1):54-61 [10620634.001]
  • [Cites] Cancer. 2000 Mar 1;88(5):1051-6 [10699894.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2629-35 [10861442.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):81-8 [11134198.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):682-8 [11157018.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1641-8 [11250992.001]
  • [Cites] J Natl Cancer Inst. 2001 Nov 21;93(22):1733-8 [11717334.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2631-8 [7680950.001]
  • [Cites] Lancet. 1993 Apr 17;341(8851):999-1002 [8096954.001]
  • [Cites] Br J Cancer. 1993 May;67(5):1098-101 [8494705.001]
  • [Cites] Eur J Cancer. 1993;29A(7):1002-5 [7684595.001]
  • [Cites] Cancer. 1993 Sep 15;72(6):1894-901 [7689921.001]
  • [Cites] J Natl Cancer Inst. 1993 Nov 17;85(22):1828-35 [7693955.001]
  • [Cites] J Clin Oncol. 1994 Jul;12(7):1390-3 [8021729.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1098-105 [8648363.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):594-603 [9053482.001]
  • [Cites] N Engl J Med. 1997 Jul 24;337(4):242-53 [9227931.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2546-52 [9215823.001]
  • [Cites] Ann Oncol. 1997 Jun;8(6):531-8 [9261521.001]
  • [Cites] Ann Oncol. 1997 Jun;8(6):555-9 [9261524.001]
  • [Cites] Semin Oncol. 1998 Apr;25(2 Suppl 4):24-32; discussion 45-8 [9578059.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2500-4 [9667270.001]
  • [Cites] Drugs. 1999 Aug;58(2):257-81 [10473019.001]
  • [Cites] Ann Oncol. 2002 Jul;13(7):1017-28 [12176779.001]
  • (PMID = 12838296.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; ICE protocol 1
  • [Other-IDs] NLM/ PMC2394224
  •  go-up   go-down


21. Verma M, Agarwal S, Mohta A: Primary mixed germ cell tumour of the liver--a case report. Indian J Pathol Microbiol; 2003 Oct;46(4):658-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mixed germ cell tumour of the liver--a case report.
  • Germ cell tumours in liver are uncommon.
  • Primary mixed malignant germ cell tumours of liver are even rare.
  • Here we describe a case of primary mixed malignant germ cell tumour of left lobe of liver in a two and half year old male boy.
  • This is the first reported case of primary mixed malignant germ cell tumour with components of yolk sac tumour and mature teratoma in an infant.
  • Ultrasonography and computed tomography of the abdomen revealed a large hepatic mass.
  • Left lobectomy of liver was done and chemotherapy was initiated.
  • Histopathology of specimen disclosed yolk sac tumour and mature teratoma.
  • Widespread intrahepatic metastasis developed and patient died due to liver dysfunction after six months of left lobectomy.
  • [MeSH-major] Germinoma / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Child, Preschool. Endodermal Sinus Tumor / pathology. Humans. Male. Teratoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15025371.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


22. Minowada S, Okano Y, Miyazaki J, Homma Y, Kitamura T: Multidisciplinary treatment of advanced testicular tumor with bulky liver metastasis. Urol Int; 2001;67(2):178-80
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidisciplinary treatment of advanced testicular tumor with bulky liver metastasis.
  • He had multiple bulky metastases in the liver and retroperitoneum with an extraordinarily elevated serum alpha-fetoprotein (23,500 ng/ml).
  • He received multidisciplinary treatment consisting of systemic chemotherapy, cytoreductive left hepatic lobectomy, percutaneous ablation therapy, transarterial chemoembolization, and external beam irradiation for median segments of the liver.
  • The efficient combination treatment normalized the tumor markers within 6 months and has maintained complete serological remission for 4.7 years.
  • [MeSH-major] Carcinoma, Embryonal / secondary. Endodermal Sinus Tumor / secondary. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Neoplasms, Multiple Primary / secondary. Teratoma / secondary. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Male. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger AG, Basel.
  • (PMID = 11490219.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


23. Tannuri AC, Tannuri U, Gibelli NE, Romão RL: Surgical treatment of hepatic tumors in children: lessons learned from liver transplantation. J Pediatr Surg; 2009 Nov;44(11):2083-7
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of hepatic tumors in children: lessons learned from liver transplantation.
  • The objective of the present study was to describe our experience in liver resections, in the light of liver transplantation, emphasizing the indications for surgery, surgical techniques, complications, and results.
  • METHODS: The medical records of 53 children who underwent liver resection for primary or metastatic hepatic tumors were reviewed.
  • After neoadjuvant chemotherapy, tumor resectability was evaluated by another CT scan.
  • Surgery was performed by surgeons competent in liver transplantation.
  • As in liver living donor operation, vascular anomalies were investigated.
  • The main arterial anomalies found were the right hepatic artery emerging from the superior mesenteric artery and left hepatic artery from left gastric artery.
  • Hilar structures were dissected very close to liver parenchyma.
  • The hepatic artery and portal vein were dissected and ligated near their entrance to the liver parenchyma to avoid damaging the hilar vessels of the other lobe.
  • During dissection of the suprahepatic veins, the venous infusion was decreased to reduce central venous pressure and potential bleeding from hepatic veins and the vena cava.
  • RESULTS: Fifty-three children with hepatic tumors underwent surgical treatment, 47 patients underwent liver resections, and in 6 cases, liver transplantation was performed because the tumor was considered unresectable.
  • Ten children presented with other malignant tumors-3 undifferentiated sarcomas, 2 hepatocellular carcinomas, 2 fibrolamellar hepatocellular carcinomas, a rhabdomyosarcoma, an immature ovarian teratoma, and a single neuroblastoma.
  • Hepatic resections included 22 right lobectomies, 9 right trisegmentectomies, 8 left lobectomies, 5 left trisegmentectomies, 2 left segmentectomies, and 1 case of monosegment (segment IV) resection.
  • CONCLUSION: The resection of hepatic tumors in children requires expertise in pediatric surgical practice, and many lessons learned from liver transplantation can be applied to hepatectomies.
  • [MeSH-major] Liver Neoplasms / surgery. Liver Transplantation / methods
  • [MeSH-minor] Age Factors. Blood Loss, Surgical. Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / surgery. Follow-Up Studies. Hepatectomy / methods. Hepatoblastoma / mortality. Hepatoblastoma / surgery. Humans. Infant. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / surgery. Postoperative Complications / etiology. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19944212.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Rivoire M, Elias D, De Cian F, Kaemmerlen P, Théodore C, Droz JP: Multimodality treatment of patients with liver metastases from germ cell tumors: the role of surgery. Cancer; 2001 Aug 1;92(3):578-87
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodality treatment of patients with liver metastases from germ cell tumors: the role of surgery.
  • BACKGROUND: The presence of liver metastases represents an independent poor risk prognostic factor for survival in patients with germ cell tumors.
  • METHODS: The clinical files of 37 patients who had undergone liver resection for the treatment of disseminated germ cell tumors were reviewed to define the indications for resection of residual liver metastases after chemotherapy in patients with germ cell tumors.
  • Twelve patients had active residual tumor, 7 patients had mature teratoma, and 18 patients had only necrosis on histologic examination.
  • Three prognostic factors were found to be significant in the univariate analysis for unfavorable outcome: the presence of pure embryonal carcinoma in the primary tumor, liver metastases measuring > 30 mm in greatest dimension at the time of surgery, and the presence of viable, active residual disease.
  • CONCLUSIONS: Because it is impossible to determine the histologic pattern of residual liver masses after chemotherapy with current imaging tools and percutaneous biopsy, patient selection for liver surgery may be undertaken according to the size of residual liver masses.
  • Male patients with masses that measure > or = 30 mm in greatest dimension represent a high-risk group of patients who are not likely to benefit from liver surgery.
  • Only male patients with masses that measure 10-29 mm in greatest dimension and all female patients with masses that measure > 10 mm in greatest dimension should be considered for liver resection.
  • [MeSH-major] Germinoma / secondary. Liver Neoplasms / secondary
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Postoperative Care. Prognosis. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11505402.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


25. Yokoi Y, Suzuki S, Baba S, Ohzeki T, Yajima S, Okada S, Okumura T, Konno H, Nakamura S: Aggressive hepatectomy for complete remission of metastatic germ cell tumor following chemotherapy: report of a case. Hepatogastroenterology; 2003 Jul-Aug;50(52):1136-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive hepatectomy for complete remission of metastatic germ cell tumor following chemotherapy: report of a case.
  • A 12-year-old girl presented with hemoperitoneum caused by disseminated liver tumors accompanying a retroperitoneal germ cell tumor and was rescued by transcatheter hepatic arterial embolization.
  • Following systemic chemotherapy, the liver tumors decreased in size and number, although the retroperitoneal tumor was resistant to therapy.
  • We simultaneously resected the retroperitoneal tumor, and the liver lesions by extended left lobectomy combined with resection of the three major (right, middle, and left) hepatic veins, while preserving the inferior right hepatic vein.
  • The postoperative course was uneventful, and liver regeneration evaluated by serial computed tomography was almost completed by three months following surgery.
  • Since complete removal of tumors critically influences the outcome in patients with mature teratoma, aggressive surgery is advocated for extensive tumors.
  • The present case clearly demonstrated that extended hepatectomy with resection of three major hepatic veins is feasible and provides an opportunity for achieving complete remission in patients with metastatic germ cell tumor of the liver.
  • [MeSH-major] Germinoma / surgery. Hepatectomy. Liver Neoplasms / surgery. Retroperitoneal Neoplasms / surgery
  • [MeSH-minor] Child. Embolization, Therapeutic. Female. Hemoperitoneum / etiology. Hemoperitoneum / therapy. Humans. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12845998.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


26. Kobayashi N, Koizumi T, Eguchi T, Hyogotani A, Saito G, Hamanaka K, Shiina T, Kurai M, Kondo R, Yoshida K, Amano J: A mediastinal somatic-type germ cell tumor with hepatic metastasis successfully treated by multiple modalities. Anticancer Res; 2010 Dec;30(12):5117-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A mediastinal somatic-type germ cell tumor with hepatic metastasis successfully treated by multiple modalities.
  • Rhabdomyosarcoma in the mediastinum coexisting with metastatic non-seminomatous germ cell tumor, so-called somatic-type malignancy, is a rare carcinoma and has poor survival.
  • This study reports a case of diffuse and huge hepatic metastasis of non-seminomatous germ cell tumor associated with coexisting embryonal rhabdomyosarcoma in the mediastinum.
  • A 31-year-old man presented with abdominal pain and was found to have multiple abnormal hepatic masses on abdominal computed tomography (CT).
  • Chemotherapy was initiated because the hepatic lesion was diagnosed as choriocarcinoma, based on histological findings and the elevation of chorionic gonadotropin β-subunit and α-fetoprotein.
  • After six cycles of bleomycin, etoposide and cisplatin chemotherapy the metastatic liver tumors showed complete response.
  • The histological findings revealed mature teratoma with embryonal rhabdomyosarcoma.
  • The patient has remained well for over six years after the treatment without any signs of disease recurrence.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Choriocarcinoma / drug therapy. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Mediastinal Neoplasms / drug therapy. Rhabdomyosarcoma, Embryonal / drug therapy. Teratoma / drug therapy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21187499.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


27. Barton SJ, Ashdown DA, Ganta S, Wallace D: An unusual presentation of metastatic testicular tumour. J R Army Med Corps; 2005 Mar;151(1):30-3
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a unique case of metastatic malignant teratoma from an undescended testis which presented with acute pulmonary embolism.
  • After chemotherapy, the undescended right testicle was resected along with a cord of non- obstructing inferior venal caval tumour which extended into the right atrium with tumour floating free within the atrium at the end of the cord of tumour.
  • The presentation, diagnosis and treatment of testicular tumours is described and the literature pertaining to testicular tumours in military personnel reviewed.
  • [MeSH-major] Carcinoma, Embryonal / diagnosis. Pulmonary Embolism / diagnosis. Pulmonary Embolism / etiology. Teratoma / diagnosis. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Humans. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Male. Military Personnel. Neoplastic Cells, Circulating. Vascular Neoplasms / diagnosis. Vascular Neoplasms / secondary. Vascular Neoplasms / surgery. Vena Cava, Inferior / pathology. Venous Thrombosis / diagnosis. Venous Thrombosis / surgery

  • MedlinePlus Health Information. consumer health - Pulmonary Embolism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15912681.001).
  • [ISSN] 0035-8665
  • [Journal-full-title] Journal of the Royal Army Medical Corps
  • [ISO-abbreviation] J R Army Med Corps
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


28. Pizzocaro G, Schiavo M, Solima S, Vitellaro M, Biasoni N, Nicolai N: [Long-term results of laparoscopic retroperitoneal lymph node dissection (RPLND) in low-stage nonseminomatous germ-cell testicular tumors (NSGCTT) performed by a senior surgeon: 1999-2003]. Urologia; 2010 Oct-Dec;77 Suppl 17:50-6
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: of the 48 operated patients, 36 had primary RPLND for clinical stage I disease (22 TIN0, 7 TxN0, 5 T2-3 N0 and 2 TIS1 N0) and 12 had post-chemotherapy surgery for IIA and IIB retroperitoneal nodes with normalized AFP and HCG.
  • No post-operative adjuvant chemotherapy was planned for patients with documented nodal metastases as for open RPLND since 1985.
  • RESULTS: Average operative time was 3.30' for the 36 clinical stage I patients and 4 hours for post-chemotherapy surgery.
  • Residual teratoma was found in 6 of the 12 patients who received neo-adjuvant chemotherapy for clinical stage IIA or IIB disease.
  • Further metastases developed in 2 of the 30 patients with negative nodes: 1 in the lung in a pT1, and 1 in a pT2 patient with increasing markers.
  • Surprisingly, the first two pT2-3 patients with positive nodes developed liver metastases in a few months after L-RPLND.
  • CONCLUSIONS: L-RPLND is a very demanding operation, which appears to be more a staging procedure than a curative operation.
  • It is ideal for pT1 clinical stage I and for post-chemotherapy stages IIA& B with residual teratoma and normalized markers, but wait & see in good risk and open RPLND in high risk patients are very competing.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Clinical Competence. Combined Modality Therapy. Follow-Up Studies. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male. Neoadjuvant Therapy. Neoplasm Staging. Orchiectomy. Retroperitoneal Space. Retrospective Studies. Teratoma / drug therapy. Teratoma / secondary. Teratoma / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21308676.001).
  • [ISSN] 1724-6075
  • [Journal-full-title] Urologia
  • [ISO-abbreviation] Urologia
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


29. Halperin EC: Neonatal neoplasms. Int J Radiat Oncol Biol Phys; 2000 Apr 1;47(1):171-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To describe neoplasms diagnosed in children </= 28 days of age along with their treatment, associated congenital anomalies, and the long-term consequences of the diagnoses and treatments.
  • The 20 patients identified via the computerized registry system for 1980-1998 constitute 2% (20/925) of all neoplasms seen in patients </= 16 years of age over this same time period at DUMC.
  • The histologic diagnoses were teratoma/germ cell tumor (n = 8, 35%), neuroblastoma (n = 5, 22%), retinoblastoma (n = 4, 17%), primary central nervous system (CNS) tumor (n = 3, 13%), and one case each of rhabdomyosarcoma, glossal glial choristoma, and hemangioma in the setting of Kasabach-Merritt Syndrome.
  • Of the eight teratoma/germ cell tumor patients, 6 were female (75%) and 2 male (25%).
  • Two of the seven patients with immature teratomas or teratoma were long-term survivors following surgery.
  • The one patient with malignant germ cell tumor, treated with surgery and chemotherapy, died.
  • Two were treated with surgery + chemotherapy + radiotherapy; two with surgery + chemotherapy; and one with surgery alone.
  • A child with a dumbbell neuroblastoma, treated with surgery and chemotherapy, is paraplegic.
  • The two children with trilateral retinoblastoma died after therapy with surgery, craniospinal and orbital irradiation, and chemotherapy.
  • Two children with bilateral disease are long-term survivors: one treated with radiotherapy + chemotherapy and one with radiotherapy alone.
  • Two of the patients are long-term survivors after surgery + chemotherapy.
  • Six children received eight courses of radiation therapy: 2 for Stage 4S neuroblastoma with respiratory compromise from an enlarging liver and 4 for retinoblastoma.
  • The two infants with trilateral retinoblastoma received two courses of irradiation each: one of the treatment of intraocular tumor and a second, at an older age, for the pineal tumor.
  • CONCLUSION: The most common neonatal neoplasm histologic diagnoses are teratoma/germ cell tumor, neuroblastoma, and retinoblastoma.
  • Radiation therapy is administered infrequently in a population highly susceptible to late ill effects.
  • When radiotherapy is required, anesthesia may be repetitively administered to aid in reproducible treatment.
  • [MeSH-minor] Anesthesia. Brain Neoplasms / epidemiology. Brain Neoplasms / pathology. Brain Neoplasms / therapy. Female. Follow-Up Studies. Hemangioma / epidemiology. Hemangioma / pathology. Hemangioma / therapy. Humans. Infant, Newborn. Male. Neuroblastoma / epidemiology. Neuroblastoma / pathology. Neuroblastoma / therapy. Registries. Retinoblastoma / epidemiology. Retinoblastoma / pathology. Retinoblastoma / therapy. Survivors. Teratoma / epidemiology. Teratoma / pathology. Teratoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10758320.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


30. Funahashi M, Tuchiya F, Makiyama K, Sugiura S, Miyoshi Y, Kishida T, Ogawa T, Uemura H, Yao M, Kubota Y: [Two cases of testicular tumors with high alpha-fetoprotein levels: a case report]. Hinyokika Kiyo; 2005 Feb;51(2):133-7
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 2002, chemotherapy was performed for a metastatic seminoma revealed as a solitary mass in the mediastinum by radiographic studies, and histologically confirmed to be a metastatic seminoma.
  • The subfraction profile with lens culinaris hemagglutinin (LCA) revealed elevation of only peak 1 which implied that the chronic hepatitis was due to liver dysfunction.
  • Case 2: In 2002, a 30-year-old male underwent left high orchiectomy for a left testicular tumor, and histological examination revealed seminoma, immature and mature teratoma, embryonal carcinoma.
  • After 2 courses of chemotherapy, the serum AFP remained at an abnormally high concentration.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Embryonal / diagnosis. Neoplasms, Multiple Primary / diagnosis. Seminoma / diagnosis. Teratoma / diagnosis. Testicular Neoplasms / diagnosis. alpha-Fetoproteins / analysis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Disease-Free Survival. Follow-Up Studies. Humans. Male. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / secondary. Orchiectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15773370.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / alpha-Fetoproteins
  •  go-up   go-down


31. Michael H, Lucia J, Foster RS, Ulbright TM: The pathology of late recurrence of testicular germ cell tumors. Am J Surg Pathol; 2000 Feb;24(2):257-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 91 men had histologically documented late recurrences of testicular germ cell tumors characterized by a complete response to treatment with a subsequent disease-free interval of at least 2 years and no evidence of a second primary lesion.
  • Ninety percent of the patients for whom information was available received chemotherapy shortly after their initial diagnosis of testicular germ cell tumors; most of the other patients were known to have stage I disease initially.
  • Overall, 60% of patients had teratoma in their late recurrences, including 20 patients (22%) in whom teratoma was the only element.
  • Thus, teratoma was the most common type of neoplasm in late recurrences.
  • Excluding teratoma coexisting with other types of neoplasms, yolk sac tumor was the most frequent type of tumor in patients with late recurrence.
  • It occurred in 47% of patients, either alone or with teratoma, another nonteratomatous germ cell tumor type, or a "nongerm cell malignant tumor."
  • Unusual types of yolk sac tumor, including glandular, parietal, clear cell, and pleomorphic patterns, were seen frequently in late recurrences and often raised differential diagnostic problems with "nongerm cell" carcinomas.
  • A smaller number of late recurrences consisted of other types of neoplasms.
  • "Nongerm cell malignant tumors," including both sarcomas and carcinomas of various types, occurred in 23% of late-recurrence patients, either alone or with a nonteratomatous germ cell tumor.
  • Late recurrences were seen in many different sites in these patients, including the retroperitoneum, abdomen, pelvis, liver, mediastinum, lung, bone (femur, vertebra, and rib), lymph nodes outside the retroperitoneum and mediastinum (supraclavicular, neck, and axillary regions), scrotum and inguinal regions, adrenal gland, chest wall, and buttocks.
  • Patients whose late recurrences consisted of teratoma only had the most favorable outcomes, with 79% having no evidence of disease at last follow-up.
  • Patients whose late recurrences consisted of pure "nongerm cell malignant tumor" or pure germ cell tumor (yolk sac tumor or other types) had a much worse prognosis: Only 36% to 37% were alive with no evidence of disease.
  • Patients with two different types of nonteratomatous malignancies in their late recurrences had a dismal clinical course: Only 17% with both yolk sac tumor and other nonteratomatous germ cell tumor had no evidence of disease, whereas no patient with both nonteratomatous germ cell tumor and "nongerm cell malignant tumor" was disease free.
  • Late recurrences consisting of teratoma alone often have a favorable outcome, but the prognosis in all other patients is poor.
  • Furthermore, late recurrence is not likely to respond to chemotherapy and is best treated by surgical excision when possible.
  • [MeSH-minor] Adolescent. Adult. Carcinoma, Embryonal / complications. Carcinoma, Embryonal / pathology. Carcinoma, Embryonal / therapy. Choriocarcinoma / complications. Choriocarcinoma / pathology. Choriocarcinoma / therapy. Endodermal Sinus Tumor / complications. Endodermal Sinus Tumor / pathology. Endodermal Sinus Tumor / therapy. Fluorescent Antibody Technique, Direct. Humans. Male. Neoplasm Staging. Neoplasms, Second Primary / pathology. Neoplasms, Second Primary / therapy. Sarcoma / complications. Sarcoma / pathology. Sarcoma / therapy. Seminoma / complications. Seminoma / pathology. Seminoma / therapy. Teratoma / complications. Teratoma / pathology. Teratoma / therapy

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10680894.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


32. Albert A, Cruz O, Montaner A, Vela A, Badosa J, Castañón M, Morales L: [Congenital solid tumors. A thirteen-year review]. Cir Pediatr; 2004 Jul;17(3):133-6
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This is an interesting group of tumors because their type, relative incidence, natural history and response to treatment differ from those seen in older children.
  • There were 8 teratomas (3 sacrocoxigeal, 1 retroperitoneal, 1 in the CNS, 1 orbitary and two oronasal), two hepatic tumors (1 hepatoblastoma, 1 hemangioendothelioma, two CNS tumors, two giant nevus (one on a hamartoma), and one each Wilms tumor, infantile fibrosarcoma and myofibroblastic tumor.
  • Treatment was surgical resection alone in 17 cases (68%) and surgery + chemotherapy in 8 (32%) (5 neuroblastomas, one CNS tumor, one Wilms tumor and one presacral teratoma who developed a yolk sac tumor); 3 patients died (11%): one at surgery, one of tumoural airway obstruction at birth and one with craniopharyngioma.
  • Among the 14 tumors that were initially not malignant, two can be locally agressive, one was an immature teratoma, the giant nevus with hamartoma developed in situ melanoma, the other nevus had meningeal melanosis with hydrocephalus, and one mature presacral teratoma developed a yolk sac tumor.
  • Complete surgical excision is the treatment of choice, most cases not need adjuvant chemotherapy.
  • [MeSH-major] Central Nervous System Neoplasms / congenital. Kidney Neoplasms / congenital. Liver Neoplasms / congenital. Neuroblastoma / congenital. Skin Neoplasms / congenital. Soft Tissue Neoplasms / congenital. Teratoma / congenital. Wilms Tumor / congenital
  • [MeSH-minor] Female. Follow-Up Studies. Humans. Infant, Newborn. Male. Neoplasm Recurrence, Local. Postoperative Complications. Pregnancy. Prenatal Diagnosis. Time Factors

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15503950.001).
  • [ISSN] 0214-1221
  • [Journal-full-title] Cirugía pediátrica : organo oficial de la Sociedad Española de Cirugía Pediátrica
  • [ISO-abbreviation] Cir Pediatr
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


33. Ishikawa M, Nakayama K, Yeasmin S, Katagiri A, Iida K, Nakayama N, Miyazaki K: [Paclitaxel + carboplatin (TC)-resistant stage Ic squamous cell carcinomas arising in mature cystic teratomas of the ovary]. Gan To Kagaku Ryoho; 2010 Apr;37(4):747-52
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant transformation of an ovarian mature cystic teratoma is very rare; it arises in about 1-2% of all dermoid cysts.
  • No standard treatment has been established for advanced and recurrent disease.
  • In Case 1, a 78-year-old woman was diagnosed with squamous cell carcinoma arising from a mature cystic teratoma of the ovary after undergoing right salpingo-oophorectomy (RSO).
  • She was treated with chemotherapy(TC), but the carcinoma recurred 2 months after completing first-line chemotherapy.
  • She began second-line chemotherapy (PEC: CBDCA+PEP+etoposide), but became disoriented on the second day of treatment, and could not complete the schedule.
  • Case 2 was a 60-year-old woman diagnosed with stage Ic disease when she underwent a computed tomography scan during chemotherapy for breast cancer recurrence in her liver.
  • She underwent bilateral salpingo-oophorectomy (BSO), and was treated with chemotherapy (TC+trastuzumab).
  • She received 5 courses, but the breast cancer metastases enlarged and her chemotherapy regimen was changed.
  • She developed ileus and underwent a colostomy.
  • She then underwent transcatheter arterial embolization via the inferior mesenteric artery and received cisplatin (100 mg/body) as second-line chemotherapy.
  • The results of TAE, however, showed that it may be an effective second-line therapy for recurrent squamous cell carcinoma arising from a mature cystic teratoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Ovarian Neoplasms / drug therapy. Paclitaxel / therapeutic use

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20414041.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


34. Buccoliero AM, Castiglione F, Maio V, Moncini D, Sardi I, Taddei A, Martin A, Messineo A, Taddei GL: Teratoid hepatoblastoma. Fetal Pediatr Pathol; 2008;27(6):274-81
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present the case of a Middle Eastern child, diagnosed and treated at 8 months of age for a hepatic neuroblastoma.
  • After surgical removal of a 7 cm mass of the left liver lobe at our institution when the child was 15 months of age, the tumor was reclassified as a teratoid hepatoblastoma.
  • The tumor was composed of fetal and embryonal hepatic tissue, undifferentiated tissue, and a teratoid background of loose mesenchymal tissue containing osteoid, squamous, and mucinous epithelium.
  • We speculate on the histogenesis of teratoid hepatoblastoma and discuss its association with chemotherapy.
  • [MeSH-major] Hepatoblastoma / diagnosis. Liver Neoplasms / diagnosis. Neuroblastoma / diagnosis. Teratoma / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Humans. Infant. Male

  • Genetic Alliance. consumer health - Hepatoblastoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19065325.001).
  • [ISSN] 1551-3823
  • [Journal-full-title] Fetal and pediatric pathology
  • [ISO-abbreviation] Fetal Pediatr Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Castex MP, Bertozzi AI, Rubie H, Domenech B, Duchayne E, Selves J, Dastugue N, Danjoux M, Kulhein E, Galinier P, Robert A: [Testicular feminization, germinal tumor, NK lymphoma: what is the relationship?]. Arch Pediatr; 2001 Dec;8(12):1337-40
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE REPORT: The authors report the case of a ten-year-old girl, who had been treated for a malignant germinal tumour five years before, presenting with a leukaemia-like syndrome associating bone pain, liver and spleen nodules and bone marrow involvement.
  • The child received several subsequent lines of chemotherapy and ultimately died of the disease.
  • [MeSH-major] Androgen-Insensitivity Syndrome / genetics. Killer Cells, Natural. Leukemia / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Ovarian Neoplasms / genetics. Teratoma / genetics
  • [MeSH-minor] Antigens, CD56 / genetics. Bone Marrow / pathology. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Child. Female. Genotype. Humans. Liver / pathology. Male. S100 Proteins / genetics

  • Genetic Alliance. consumer health - Testicular Feminization.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11811029.001).
  • [ISSN] 0929-693X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / S100 Proteins
  •  go-up   go-down


36. Yalçin B, Kutluk MT, Ariyürek M, Göğüş S, Büyükpamukçu M: Metastatic endodermal sinus tumor: CT appearances. Turk J Pediatr; 2002 Oct-Dec;44(4):343-5
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A one-week-old boy had undergone resection of a sacrococcygeal benign cystic teratoma.
  • Postoperatively, massively enlarged inguinal lymph nodes and abdominal distention developed.
  • Computerized tomography displayed enlarged inguinal lymph nodes, metastatic lesions in the liver, and a pelvic recurrent mass.
  • He received BEP (bleomycin, etoposide, cisplatin) chemotherapy regimen, and a complete remission was achieved with a normal serum alpha-fetoprotein.
  • Close follow-up and serum alpha-fetoprotein monitoring are mandatory after the resection of a sacrococcygeal teratoma.
  • [MeSH-major] Endodermal Sinus Tumor / radiography. Liver Neoplasms / secondary. Neoplasms, Second Primary / radiography. Pelvic Neoplasms / radiography
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Etoposide / therapeutic use. Humans. Infant. Male. Sacrococcygeal Region. Tomography, X-Ray Computed. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12458813.001).
  • [ISSN] 0041-4301
  • [Journal-full-title] The Turkish journal of pediatrics
  • [ISO-abbreviation] Turk. J. Pediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / alpha-Fetoproteins; 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


37. You YN, Leibovitch BC, Que FG: Hepatic metastasectomy for testicular germ cell tumors: is it worth it? J Gastrointest Surg; 2009 Apr;13(4):595-601
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic metastasectomy for testicular germ cell tumors: is it worth it?
  • BACKGROUND: Chemotherapy is highly effective for metastatic germ cell tumor (GCT), but experience with resection of hepatic metastases from GCT is limited.
  • METHODS: Fifteen patients with GCT metastatic to the liver underwent 16 hepatic operations (1975-2002).
  • Pre-resection therapy, surgical pathology, and operative outcomes were reviewed.
  • Hepatic histology included: necrosis (33%), viable tumor (27%), mature teratoma (13%), and benign histology (27%).
  • Concomitant resection of extrahepatic disease (14 patients, 93%) found necrosis (53%), mature teratoma (27%), and viable tumor (13%).
  • CONCLUSION: Resection of post-chemotherapy hepatic disease is safe, even when combined with resection of extrahepatic residual disease.
  • The varied histologic findings, lack of reliable predictors, and prolonged survival achieved support a multidisciplinary approach which includes surgical resection of hepatic metastases.
  • [MeSH-major] Hepatectomy. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Neoplasms, Germ Cell and Embryonal / secondary

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2005 Aug;242(2):260-6 [16041217.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):594-603 [9053482.001]
  • [Cites] N Engl J Med. 1997 Jul 24;337(4):242-53 [9227931.001]
  • [Cites] J Urol. 2004 Jan;171(1):168-71 [14665869.001]
  • [Cites] J Urol. 2004 May;171(5):1835-8 [15076288.001]
  • [Cites] Ann Surg. 2008 Jan;247(1):125-35 [18156932.001]
  • [Cites] J Clin Oncol. 2006 Dec 10;24(35):5512-8 [17158536.001]
  • [Cites] Ann Thorac Surg. 1998 Nov;66(5):1709-14 [9875776.001]
  • [Cites] J Urol. 2006 Nov;176(5):1921-6 [17070212.001]
  • [Cites] J Clin Oncol. 2007 Dec 10;25(35):5603-8 [17998544.001]
  • [Cites] Cancer. 2003 Jan 1;97(1):63-70 [12491506.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):578-87 [11505402.001]
  • [Cites] Curr Ther Endocrinol Metab. 1997;6:387-92 [9174777.001]
  • [Cites] J Clin Oncol. 2007 Mar 20;25(9):1033-7 [17261854.001]
  • [Cites] Ann Surg. 1990 Sep;212(3):290-3; discussion 293-4 [2168694.001]
  • [Cites] Urol Clin North Am. 2007 May;34(2):235-43; abstract x [17484928.001]
  • [Cites] Ann Surg Oncol. 2008 Jan;15(1):207-18 [17963007.001]
  • [Cites] J Pathol. 2007 Sep;213(1):65-71 [17634958.001]
  • [Cites] Ann Oncol. 2006 Sep;17 Suppl 10:x31-5 [17018745.001]
  • [Cites] Urol Clin North Am. 2007 May;34(2):199-217; abstract ix [17484925.001]
  • [Cites] Surgery. 2007 Jan;141(1):9-18 [17188163.001]
  • [Cites] Semin Urol Oncol. 2002 Nov;20(4):262-71 [12489059.001]
  • [Cites] Ann Surg Oncol. 1999 Oct-Nov;6(7):640-4 [10560848.001]
  • [Cites] Urol Clin North Am. 2007 May;34(2):187-97; abstract ix [17484924.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1377-99 [15319245.001]
  • (PMID = 19190967.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Kinoshita Y, Tajiri T, Souzaki R, Tatsuta K, Higashi M, Izaki T, Takahashi Y, Taguchi T: Diagnostic value of lectin reactive alpha-fetoprotein for neoinfantile hepatic tumors and malignant germ cell tumors: preliminary study. J Pediatr Hematol Oncol; 2008 Jun;30(6):447-50
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of lectin reactive alpha-fetoprotein for neoinfantile hepatic tumors and malignant germ cell tumors: preliminary study.
  • RESULTS: In all cases of hepatoblastoma and yolk sac tumor, both the total AFP and the L3 fraction were high, either before treatment or in the presence of malignant tumors.
  • Most of the cases of neonatal immature teratoma showed a high total AFP level during the neoinfantile period, however, the L3 fraction was around 10%, and decreased after surgical treatment.
  • Only 1 case of the immature teratoma demonstrated malignant transformation, when the patient was 8 months old.
  • As the total AFP and the AFP-L3 fraction were proportionally elevated, the patient was treated with additional surgical resection and chemotherapy.
  • In the case of neonatal mature teratoma, the L3 fraction was below 0.5%, even when the total AFP level was high.
  • DISCUSSION: Our results indicated that the level of the L3 fraction accurately confirmed the existence, or the malignant potential of hepatic tumor or germ cell tumor.
  • [MeSH-major] Biomarkers, Tumor / blood. Hepatoblastoma / blood. Liver Neoplasms / blood. Neoplasms, Germ Cell and Embryonal / blood. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18525461.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Lectins; 0 / Protein Isoforms; 0 / alpha-Fetoproteins
  •  go-up   go-down


39. Yamamoto H, Quinn G, Asari A, Yamanokuchi H, Teratani T, Terada M, Ochiya T: Differentiation of embryonic stem cells into hepatocytes: biological functions and therapeutic application. Hepatology; 2003 May;37(5):983-93
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of embryonic stem cells into hepatocytes: biological functions and therapeutic application.
  • Embryonic stem (ES) cells provide a unique source for tissue regeneration.
  • After transplantation into the carbon tetrachloride-injured mouse liver, ES-derived green fluorescent protein-positive cells were incorporated into liver tissue and rescued mice from hepatic injury.
  • No teratoma formation was observed in the transplant recipients.
  • In conclusion, ES cells can provide a valuable tool for studying the molecular basis for differentiation of hepatocytes and form the basis for cell therapies.
  • [MeSH-major] Drug-Induced Liver Injury / therapy. Hepatocytes / cytology. Stem Cell Transplantation. Stem Cells / cytology
  • [MeSH-minor] Albumins / genetics. Animals. Carbon Tetrachloride. Cell Differentiation. Cells, Cultured. Female. Green Fluorescent Proteins. Immunohistochemistry. Indicators and Reagents / metabolism. Liver Regeneration. Luminescent Proteins / genetics. Male. Mice. Mice, Inbred Strains

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • Hazardous Substances Data Bank. CARBON TETRACHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12717379.001).
  • [ISSN] 0270-9139
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Albumins; 0 / Indicators and Reagents; 0 / Luminescent Proteins; 147336-22-9 / Green Fluorescent Proteins; CL2T97X0V0 / Carbon Tetrachloride
  •  go-up   go-down


40. Neto EB, de Carvalho CM, Belo MT, Vieira AF, de Oliveira TB, Pereira MC, Leal GM, Branco MM: [A rare case of intrapulmonary fetus-in-fetu]. Rev Port Pneumol; 2005 May-Jun;11(3):321-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A few cases have been reported in the cranial cavity, cervical spine, ovarium, scrotum and liver.
  • We presently report a case of intrapulmonary FIF in a 12-year-old girl who was on treatment for pulmonary tuberculosis and had no symptoms related to the tumor.
  • [MeSH-major] Fetus / abnormalities. Lung Neoplasms / pathology. Teratoma / pathology
  • [MeSH-minor] Child. Female. Humans. Tuberculosis, Pulmonary / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16027949.001).
  • [ISSN] 0873-2159
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


41. Perek D, Brozyna A, Dembowska-Baginska B, Stypinska M, Sojka M, Bacewicz L, Polnik D, Kalicinski P: [Tumours in newborns and infants up to three months of life. One institution experience]. Med Wieku Rozwoj; 2006 Jul-Sep;10(3 Pt 1):711-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Newborns and infants up to three months of life are a specific group of population in paediatric oncology due to immaturity of tissues and organs and rarity of neoplastic diseases in this group of patients (pts).
  • There are no strict therapeutic procedures established for these children.
  • THE AIM of our study was to examine distribution of tumours in newborns and infants up to 3 months of age treated in our institution and to present our own experience in the treatment of these patients.
  • Distribution of tumour types in newborns and babies from 1 to 3 months of age was analyzed separately.
  • Due to similar growth pattern, response to treatment and it's side effects in newborns and small infants, treatment results were evaluated for the whole group.
  • There were also 3 cases of soft tissue sarcomas (STS), 2 central nervous system tumours (CNS), 2 retinoblastoma (RB), 2 hepatoblastoma (HB).
  • In the group of 21 babies aged 1-3 months NBL was the commonest (37%) followed by RB, CNS tumours (14% of each) HB and MT (10% of each) and Wilms tumour (WT) and immature teratoma (IT) each 5%.
  • Eleven pts underwent combined treatment of chemotherapy and surgery: 5 with stage III and IV NBL, 6 with other tumours.
  • Chemotherapy alone was administered to 7 pts in whom local advancement of disease enabled surgery and to pts with RBL.
  • Four pts with NBL (2 stage IV and 2 stage IVS) were treated with irradiation to the liver only.
  • One pt, critically ill, died before any treatment.
  • 2. Newborns and small infants with advanced neoplastic disease, similarly to older children can be cured with chemotherapy.
  • 3. Individual approach is warranted in newborns and small infants and treatment should be carried out in specialized centres.
  • 4. All patients who completed treatment of any tumour type should be followed up by a pediatric oncologist.
  • [MeSH-major] Infant Welfare / statistics & numerical data. Neoplasms / epidemiology. Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317902.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


42. Liu H, Ye Z, Kim Y, Sharkis S, Jang YY: Generation of endoderm-derived human induced pluripotent stem cells from primary hepatocytes. Hepatology; 2010 May;51(5):1810-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patient-specific iPS cells have been derived not only for disease modeling but also as sources for cell replacement therapy.
  • Here we show for the first time reprogramming of human endoderm-derived cells (i.e., primary hepatocytes) to pluripotency.
  • Hepatocyte-derived iPS cells appear indistinguishable from hES cells with respect to colony morphology, growth properties, expression of pluripotency-associated transcription factors and surface markers, and differentiation potential in embryoid body formation and teratoma assays.
  • In addition, these cells are able to directly differentiate into definitive endoderm, hepatic progenitors, and mature hepatocytes.
  • CONCLUSION: The technology to develop endoderm-derived human iPS cell lines, together with other established cell lines, will provide a foundation for elucidating the mechanisms of cellular reprogramming and for studying the safety and efficacy of differentially originated human iPS cells for cell therapy.
  • For the study of liver disease pathogenesis, this technology also provides a potentially more amenable system for generating liver disease-specific iPS cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2009 Oct 1;461(7264):649-3 [19718018.001]
  • [Cites] Cell Res. 2009 Nov;19(11):1233-42 [19736565.001]
  • [Cites] Nat Biotechnol. 2009 Nov;27(11):1033-7 [19826408.001]
  • [Cites] Nat Genet. 2009 Dec;41(12):1350-3 [19881528.001]
  • [Cites] Cell Stem Cell. 2009 Dec 4;5(6):584-95 [19951687.001]
  • [Cites] Blood. 2009 Dec 24;114(27):5473-80 [19797525.001]
  • [Cites] Hepatology. 2010 Jan;51(1):329-35 [19877180.001]
  • [Cites] Nat Genet. 2002 Oct;32(2):312-5 [12355088.001]
  • [Cites] Cancer Res. 1993 Jun 15;53(12):2884-7 [8389246.001]
  • [Cites] Oncogene. 2006 Jun 26;25(27):3778-86 [16799619.001]
  • [Cites] Cell. 2006 Aug 25;126(4):663-76 [16904174.001]
  • [Cites] Cell. 2007 Nov 30;131(5):861-72 [18035408.001]
  • [Cites] Science. 2007 Dec 21;318(5858):1917-20 [18029452.001]
  • [Cites] Nature. 2008 Jan 10;451(7175):141-6 [18157115.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):2883-8 [18287077.001]
  • [Cites] Stem Cells. 2008 May;26(5):1117-27 [18292207.001]
  • [Cites] Expert Opin Drug Metab Toxicol. 2008 Jul;4(7):855-70 [18624675.001]
  • [Cites] Science. 2008 Aug 1;321(5889):699-702 [18276851.001]
  • [Cites] Nat Biotechnol. 2008 Aug;26(8):916-24 [18594521.001]
  • [Cites] Nat Biotechnol. 2008 Nov;26(11):1276-84 [18931654.001]
  • [Cites] Nature. 2009 Jan 8;457(7226):200-4 [19020503.001]
  • [Cites] Nat Biotechnol. 2009 Apr;27(4):353-60 [19330000.001]
  • [Cites] Cell Stem Cell. 2009 Jul 2;5(1):111-23 [19570518.001]
  • [Cites] Nat Biotechnol. 2009 Aug;27(8):743-5 [19590502.001]
  • [Cites] PLoS One. 2009;4(9):e7076 [19763270.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):136-45 [11443619.001]
  • [CommentIn] Hepatology. 2010 Sep;52(3):1169; author reply 1169-70 [20812362.001]
  • (PMID = 20432258.001).
  • [ISSN] 1527-3350
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK070971-04; United States / NIDDK NIH HHS / DK / R01 DK070971; United States / NIDDK NIH HHS / DK / DK O70971; United States / NIDDK NIH HHS / DK / R01 DK070971-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HGF protein, human; 0 / activin A; 104625-48-1 / Activins; 62229-50-9 / Epidermal Growth Factor; 67256-21-7 / Hepatocyte Growth Factor
  • [Other-IDs] NLM/ NIHMS221023; NLM/ PMC2925460
  •  go-up   go-down






Advertisement